Advanced Materials Science Research

Current Reviews In Pharmacoproteomics

 Proteomics is defined because the study of proteins and their variability in human disease states. The proteome may vary between different individuals, different organs, or maybe between cells within the same organ in a private. Pharmacoproteomics is rapidly increasing the advancements within the sector during the techniques of proteomics are applying to develop the pharmaceutical agents. Pharmacoproteomics could also be a more functional representation of patient-to-patient variation than that provided by genotyping. Pharmacoproteomics methodology is providing an important quantitative data on protein expression patterns in response to a given pharmaceutical stimulus also as qualitative information on post-translational modifications to each protein. This is providing an information on signaling cascades triggered independently of protein neosynthesis and data on early cellular events just like the stimulus. Proteomes are therefore dynamic, and a given human may have a proteome with as many as two million proteins. The use of this full set of proteins to review the effect of disease or drugs can substitute for far more complex assays in pharmacodynamics at a lower cost in time, financial output, and clinical risk. Some of the apparent advantages of studying pharmacoproteomics include the power to predict which drugs are going to be ultimately useful in humans, by revealing the pharmacokinetics, bioavailability, metabolism, and adverse or side effects of new or novel therapeutic agents in the preclinical stage. This is made possible by the power to review how drugs work on the extent of protein expression, while simultaneously deciphering their toxicity and resistance to their cellular mechanism of action, early within the drug development process instead of after a protracted and dear preclinical testing phase.

High Impact List of Articles

Relevant Topics in General Science